A phase II study of bevacizumab (BEV) plus erlotinib (ERL) in patients with gemcitabine (GEM)-refractory metastatic pancreatic cancer (MPC)

被引：0
|
作者：
Ko, A. H. [1 ]
Dito, E. [1 ]
Schillinger, B. [1 ]
Venook, A. P. [1 ]
Bergsland, E. K. [1 ]
Korn, W. M. [1 ]
Tempero, M. A. [1 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4516
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer
    El-Rayes, Bassel Fuad
    Philip, Philip A.
    Sarkar, Fazlul H.
    Shields, Anthony F.
    Ferris, Ann Marie
    Hess, Kenneth
    Kaseb, Ahmad O.
    Javle, Milind M.
    Varadhachary, Gauri R.
    Wolff, Robert A.
    Abbruzzese, James L.
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (04) : 694 - 699
  • [32] Phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma
    Kim, G. P.
    Oberg, A. L.
    Foster, N. R.
    Jaslowski, A.
    Flynn, P. J.
    Campbell, D.
    Hedrick, E.
    Gray, L.
    Grothey, A.
    Alberts, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] Randomized phase II study of best available fluoropyrimidine compared with continuation of gemcitabine (Gem) monotherapy in patients with Gem-refractory pancreatic cancer
    Ioka, Tatsuya
    Katayama, Kazuhiro
    Ishida, Nobuko
    Takada, Ryoji
    Yamai, Takuo
    Fukutake, Nobuyasu
    Ashida, Reiko
    Uehara, Hiroyuki
    Ohigashi, Hiroaki
    Takahashi, Hidenori
    Ishikawa, Osamu
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [34] A multicenter phase II study of erlotinib and bevacizumab in patients with metastatic melanoma
    Wyman, K.
    Spigel, D.
    Puzanov, I.
    Hainsworth, J.
    Kelley, M.
    Krozely, P.
    Sturgeon, D.
    Sosman, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [35] Phase II presurgical study of bevacizumab plus erlotinib in untreated patients with metastatic renal cell carcinoma
    Jonasch, E.
    Tsavachdidou, D.
    Wood, C. G.
    Matin, S. F.
    Corn, P. G.
    Tamboli, P.
    Wang, X.
    Tannir, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] A multicenter randomized phase II trial on Kanglaite Injection (KLT) plus gemcitabine hydrochloride (GEM) versus GEM in patients with local advanced and metastatic pancreatic cancer
    Sun, Y.
    Li, Y.
    Qin, S.
    Ma, D.
    Jiao, S. C.
    Yu, S. Y.
    Li, J.
    Liu, D.
    Song, D.
    Li, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [37] Bevacizumab plus gemcitabine and capecitabine in patients with advanced pancreatic cancer with ECOG PS 0/1: A phase II study
    Javle, M. M.
    Garrett, C. R.
    Chodkiewicz, C.
    Wallace, P. K.
    Yu, J.
    Pande, A. U.
    Phelan, J. T.
    Litwin, A. M.
    Gibbs, J. F.
    Iyer, R. V.
    ANNALS OF ONCOLOGY, 2006, 17 : 310 - 310
  • [38] Updated survival analysis of preoperative gemcitabine (gem) plus bevacizumab (bev)-based chemoradiation for resectable pancreatic adenocarcinoma
    Shroff, Rachna T.
    Varadhachary, Gauri R.
    Crane, Christopher H.
    Lee, Jeffrey Edwin
    Lee, Jeffrey H.
    Ho, Linus
    Tamm, Eric P.
    Evans, Douglas B.
    Abbruzzese, James L.
    Wolff, Robert A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [39] PHASE II STUDY OF BEVACIZUMAB plus OXALIPLATIN PLUS CAPECITABINE FOLLOWED BY BEVACIZUMAB plus ERLOTINIB AS FIRST-LINE TREATMENT IN METASTATIC COLORECTAL CANCER
    Munoz, A.
    Pericay, C.
    Llorente, B.
    Alonso, V
    Duenas, R.
    Roca, J.
    Rivera, F.
    Falco, E.
    Alvarez, I
    Salud, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 73 - 74
  • [40] CONATUMUMAB (CON) OR AMG 479 OR PLACEBO (PBO) plus GEMCITABINE (GEM) IN PATIENTS (PTS) WITH METASTATIC PANCREATIC CANCER (MPC): A PLACEBO-CONTROLLED, RANDOMIZED, PHASE 2 STUDY
    Kindler, H.
    Richards, D.
    Stephenson, J.
    Garbo, L.
    Garon, E.
    Lima, C. Rocha
    Safran, H.
    Feigal, E.
    Bray, S.
    Fuchs, C.
    ANNALS OF ONCOLOGY, 2010, 21 : 233 - 234
12345